Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30; PMID:23335087; http://dx.doi.org/10.3322/caac.21166
   PubMed Web of Science ®Google Scholar
• Seve P, Reiman T, Dumontet C. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 2010; 67:136-43; PMID:19828208; http://dx.doi.org/10.1016/j.lungcan.2009.09.007
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-79; PMID:14576837; http://dx.doi.org/10.1038/sj.onc.1206933
   PubMed Web of Science ®Google Scholar
• Xiao X, Yu S, Li S, Wu J, Ma R, Cao H, Zhu Y, Feng J. Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin. PloS one 2014; 9:e89534; PMID:24586853; http://dx.doi.org/10.1371/journal.pone.0089534
   PubMed Web of Science ®Google Scholar
• Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31; PMID:17336087; http://dx.doi.org/10.1016/j.critrevonc.2007.02.001
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
   PubMed Web of Science ®Google Scholar
• Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20; PMID:15652477; http://dx.doi.org/10.1016/j.cell.2004.12.035
   PubMed Web of Science ®Google Scholar
• Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39:D152-7; PMID:21037258; http://dx.doi.org/10.1093/nar/gkq1027
   PubMed Web of Science ®Google Scholar
• Li X, Zhang J, Gao L, McClellan S, Finan MA, Butler TW, Owen LB, Piazza GA, Xi Y. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ 2012; 19:378-86; PMID:21979467; http://dx.doi.org/10.1038/cdd.2011.127
   PubMed Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438:685-9; PMID:16258535; http://dx.doi.org/10.1038/nature04303
   PubMed Web of Science ®Google Scholar
• Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansen HF, Berger U, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-9; PMID:18368051; http://dx.doi.org/10.1038/nature06783
   PubMed Web of Science ®Google Scholar
• Lee YS, Dutta A. MicroRNAs: small but potent oncogenes or tumor suppressors. Curr Opin Investig Drugs 2006; 7:560-4; PMID:16784027
   PubMed Web of Science ®Google Scholar
• Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005; 11:712-4; PMID:16015356; http://dx.doi.org/10.1038/nm0705-712
   PubMed Web of Science ®Google Scholar
• van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, et al. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene 2013; 32:4284-93; PMID:23045278; http://dx.doi.org/10.1038/onc.2012.433
   PubMed Web of Science ®Google Scholar
• Zhang Y, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. FEBS Lett 2013; 587:3069-75; PMID:23932924; http://dx.doi.org/10.1016/j.febslet.2013.06.058
   PubMed Web of Science ®Google Scholar
• Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q, et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 2012; 31:432-45; PMID:21725369; http://dx.doi.org/10.1038/onc.2011.263
   PubMed Web of Science ®Google Scholar
• Yang Y, Li H, Hou S, Hu B, Liu J, Wang J. The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PloS One 2013; 8:e65309.
   PubMed Web of Science ®Google Scholar
• Jiang W, Zhang Y, Meng F, Lian B, Chen X, Yu X, Dai E, Wang S, Liu X, Li X, et al. Identification of active transcription factor and miRNA regulatory pathways in Alzheimer disease. Bioinformatics 2013; 29:2596-602; PMID:23990414; http://dx.doi.org/10.1093/bioinformatics/btt423
   PubMed Web of Science ®Google Scholar
• Safran M, Solomon I, Shmueli O, Lapidot M, Shen-Orr S, Adato A, Ben-Dor U, Esterman N, Rosen N, Peter I, et al. GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics 2002; 18:1542-3; PMID:12424129; http://dx.doi.org/10.1093/bioinformatics/18.11.1542
   PubMed Web of Science ®Google Scholar
• Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q. An analysis of human microRNA and disease associations. Plos One 2008; 3:e3420; PMID:18923704; http://dx.doi.org/10.1371/journal.pone.0003420
   PubMed Web of Science ®Google Scholar
• Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37:D98-104; PMID:18927107; http://dx.doi.org/10.1093/nar/gkn714
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. Plos One 2012; 7:e36530; PMID:22590557; http://dx.doi.org/10.1371/journal.pone.0036530
   PubMed Web of Science ®Google Scholar
• Amelio I, Gostev M, Knight RA, Willis AE, Melino G, Antonov AV. DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis 2014; 5:e1051; PMID:24503543; http://dx.doi.org/10.1038/cddis.2014.9
   PubMed Web of Science ®Google Scholar
• Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105; PMID:18955434; http://dx.doi.org/10.1101/gr.082701.108
   PubMed Web of Science ®Google Scholar
• Fedele M, Pierantoni GM, Visone R, Fusco A. E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression. Cell Div 2006; 1:17; PMID:16914062; http://dx.doi.org/10.1186/1747-1028-1-17
   PubMed Web of Science ®Google Scholar
• Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006; 9:459-71; PMID:16766265; http://dx.doi.org/10.1016/j.ccr.2006.04.024
   PubMed Web of Science ®Google Scholar
• Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, Yatabe Y, Takahashi T. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009; 27:2793-9; PMID:19414676; http://dx.doi.org/10.1200/JCO.2008.19.7053
   PubMed Web of Science ®Google Scholar
• Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med 2014; 46:372-83; PMID:24897931; http://dx.doi.org/10.3109/07853890.2014.912836
   PubMed Web of Science ®Google Scholar
• Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 2008; 135:1322-32; PMID:18722373; http://dx.doi.org/10.1053/j.gastro.2008.07.012
   PubMed Web of Science ®Google Scholar
• Belkhiri A, Dar AA, Zaika A, Kelley M, El-Rifai W. t-Darpp promotes cancer cell survival by upregulation of Bcl2 through Akt-dependent mechanism. Cancer Res 2008; 68:395-403; PMID:18199533; http://dx.doi.org/10.1158/0008-5472.CAN-07-1580
   PubMed Web of Science ®Google Scholar
• Gommans WM, Berezikov E. Controlling miRNA regulation in disease. Methods Mol Biol 2012; 822:1-18; PMID:22144188; http://dx.doi.org/10.1007/978-1-61779-427-8_1
   PubMedGoogle Scholar
• Bao B, Ali S, Banerjee S, Wang Z, Logna F, Azmi AS, Kong D, Ahmad A, Li Y, Padhye S, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012; 72:335-45; PMID:22108826; http://dx.doi.org/10.1158/0008-5472.CAN-11-2182
   PubMed Web of Science ®Google Scholar
• Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, Chen YC, Peng Y, Yao KT, Kung HF, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71:225-33; PMID:21199804; http://dx.doi.org/10.1158/0008-5472.CAN-10-1850
   PubMed Web of Science ®Google Scholar
• Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ, Zhao Q. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011; 32:2-9; PMID:20952513; http://dx.doi.org/10.1093/carcin/bgq209
   PubMed Web of Science ®Google Scholar
• Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, Chen T, Luo Y. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205:113-23; PMID:22469510; http://dx.doi.org/10.1016/j.cancergen.2012.01.002
   PubMed Web of Science ®Google Scholar
• Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137:1005-17; PMID:19524505; http://dx.doi.org/10.1016/j.cell.2009.04.021
   PubMed Web of Science ®Google Scholar
• Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 2013; 58:158-70; PMID:23389848; http://dx.doi.org/10.1002/hep.26305
   PubMed Web of Science ®Google Scholar
• Ashar HR, Chouinard RA, Jr., Dokur M, Chada K. In vivo modulation of HMGA2 expression. Biochim Biophys Acta 2010; 1799:55-61; PMID:20123068; http://dx.doi.org/10.1016/j.bbagrm.2009.11.013
   PubMed Web of Science ®Google Scholar
• Li O, Vasudevan D, Davey CA, Droge P. High-level expression of DNA architectural factor HMGA2 and its association with nucleosomes in human embryonic stem cells. Genesis 2006; 44:523-9; PMID:17078040; http://dx.doi.org/10.1002/dvg.20242
   PubMed Web of Science ®Google Scholar
• Eda A, Tamura Y, Yoshida M, Hohjoh H. Systematic gene regulation involving miRNAs during neuronal differentiation of mouse P19 embryonic carcinoma cell. Biochem Biophys Res Commun 2009; 388:648-53; PMID:19679099; http://dx.doi.org/10.1016/j.bbrc.2009.08.040
   PubMed Web of Science ®Google Scholar
• Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007; 7:899-910; PMID:18004397; http://dx.doi.org/10.1038/nrc2271
   PubMed Web of Science ®Google Scholar
• Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198:142-56; PMID:12237873; http://dx.doi.org/10.1002/path.1121
   PubMed Web of Science ®Google Scholar
• Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene 2001; 20:1678-87; PMID:11313916; http://dx.doi.org/10.1038/sj.onc.1204242
   PubMed Web of Science ®Google Scholar
• Suh DS, Yoon MS, Choi KU, Kim JY. Significance of E2F-1 overexpression in epithelial ovarian cancer. Int J Gynecol Cancer 2008; 18:492-8; PMID:17692085; http://dx.doi.org/10.1111/j.1525-1438.2007.01044.x
   PubMed Web of Science ®Google Scholar
• Real S, Meo-Evoli N, Espada L, Tauler A. E2F1 regulates cellular growth by mTORC1 signaling. Plos One 2011; 6:e16163; PMID:21283628; http://dx.doi.org/10.1371/journal.pone.0016163
   PubMedGoogle Scholar
• Hirano G, Izumi H, Kidani A, Yasuniwa Y, Han B, Kusaba H, Akashi K, Kuwano M, Kohno K. Enhanced expression of PCAF endows apoptosis resistance in cisplatin-resistant cells. Mol Cancer Res 2010; 8:864-72; PMID:20530585; http://dx.doi.org/10.1158/1541-7786.MCR-09-0458
   PubMed Web of Science ®Google Scholar
• Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19:649-57; PMID:18032011; http://dx.doi.org/10.1016/j.ceb.2007.10.006
   PubMed Web of Science ®Google Scholar
• Polager S, Ginsberg D. E2F - at the crossroads of life and death. Trends Cell Biol 2008; 18:528-35; PMID:18805009; http://dx.doi.org/10.1016/j.tcb.2008.08.003
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499-511; PMID:9832503; http://dx.doi.org/10.1101/gad.12.22.3499
   PubMed Web of Science ®Google Scholar
• Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-9; PMID:8524413; http://dx.doi.org/10.1038/378785a0
   PubMed Web of Science ®Google Scholar
• Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 1999; 39:295-312; PMID:10331086; http://dx.doi.org/10.1146/annurev.pharmtox.39.1.295
   PubMed Web of Science ®Google Scholar
• Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001; 3:973-82; PMID:11715018; http://dx.doi.org/10.1038/ncb1101-973
   PubMed Web of Science ®Google Scholar
• Fraser M, Bai T, Tsang BK. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008; 122:534-46; PMID:17918180; http://dx.doi.org/10.1002/ijc.23086
   PubMed Web of Science ®Google Scholar
• Bansal N, Marchion DC, Bicaku E, Xiong Y, Chen N, Stickles XB, Sawah EA, Wenham RM, Apte SM, Gonzalez-Bosquet J, et al. BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J Gynecol Oncol 2012; 23:35-42; PMID:22355465; http://dx.doi.org/10.3802/jgo.2012.23.1.35
   PubMed Web of Science ®Google Scholar
• Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, Llobet-Navas D, Rajbhandari P, Bansal M, Guarnieri P, Silva J, et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011; 147:370-81; PMID:22000015; http://dx.doi.org/10.1016/j.cell.2011.09.041
   PubMed Web of Science ®Google Scholar
• Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003; 19:2448-55; PMID:14668230; http://dx.doi.org/10.1093/bioinformatics/btg345
   PubMed Web of Science ®Google Scholar
• Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, Gehan EA, Wang Y. The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer 2008; 8:37-49; PMID:18097463; http://dx.doi.org/10.1038/nrc2294
   PubMed Web of Science ®Google Scholar
• Yang H, Crawford N, Lukes L, Finney R, Lancaster M, Hunter KW. Metastasis predictive signature profiles pre-exist in normal tissues. Clin Exp Metastasis 2005; 22:593-603; PMID:16475030; http://dx.doi.org/10.1007/s10585-005-6244-6
   PubMed Web of Science ®Google Scholar
• Wingender E, Chen X, Hehl R, Karas H, Liebich I, Matys V, Meinhardt T, Prüss M, Reuter I, Schacherer F. TRANSFAC: an integrated system for gene expression regulation. Nucleic Acids Res 2000; 28:316-9; PMID:10592259; http://dx.doi.org/10.1093/nar/28.1.316
   PubMed Web of Science ®Google Scholar
• Wang J, Lu M, Qiu C, Cui Q. TransmiR: a transcription factor-microRNA regulation database. Nucleic Acids Res 2010; 38:D119-22; PMID:19786497; http://dx.doi.org/10.1093/nar/gkp803
   PubMed Web of Science ®Google Scholar
• Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011; 39:D163-9; PMID:21071411; http://dx.doi.org/10.1093/nar/gkq1107
   PubMed Web of Science ®Google Scholar
• Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37:D105-10; PMID:18996891; http://dx.doi.org/10.1093/nar/gkn851
   PubMed Web of Science ®Google Scholar
• Sethupathy P, Corda B, Hatzigeorgiou AG. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 2006; 12:192-7; PMID:16373484; http://dx.doi.org/10.1261/rna.2239606
   PubMed Web of Science ®Google Scholar